Training activity information
Details
Select, perform and interpret diagnostic techniques for the investigation of mature lymphoid neoplasms to include:
- Chronic lymphocytic leukaemia
- Monoclonal B lymphocytosis
- Plasma cell myeloma
Type
Developmental training activity (DTA)
Evidence requirements
Evidence the activity has been undertaken by the trainee.
Reflection on the activity at one or more time points after the event including learning from the activity and/or areas of the trainees practice for development.
An action plan to implement learning and/or to address skills or knowledge gaps identified.
Considerations
- Morphological features associated with lymphoproliferative
- The sample type required and the preanalytical variables affecting results
- Clinical presentations and other investigations
- National and international guidelines
- WHO classification
- Local SOPs
- Quality assurance
- Prioritisation and communication of results
Reflective practice guidance
The guidance below is provided to support reflection at different time points, providing you with questions to aid you to reflect for this training activity. They are provided for guidance and should not be considered as a mandatory checklist. Trainees should not be expected to provide answers to each of the guidance questions listed.
Before action
- What background knowledge of the classification, diagnostic criteria, and relevant laboratory techniques for CLL, MBL, and plasma cell myeloma, including flow cytometry, serum protein electrophoresis, and bone marrow assessment, is needed?
- What insights do you hope to gain regarding the specific diagnostic pathways for these different entities and the differential diagnoses? What is your current understanding of the key diagnostic features and markers for these conditions?
- How will you prepare for this activity (e.g., reviewing diagnostic criteria, understanding the role of different laboratory tests)? What potential difficulties might you face in selecting the most appropriate techniques or interpreting the results to distinguish between these related disorders, and how will you plan to address these? How do you feel about investigating this spectrum of lymphoid malignancies?
In action
- Based on the clinical presentation and initial laboratory findings, which diagnostic tests are you choosing to investigate mature lymphoid neoplasms? What are the key distinguishing features you are looking for?
- As you obtain results from various techniques (e.g., morphology, flow cytometry, serum electrophoresis, bone marrow biopsy), how are you integrating this information to differentiate between CLL, MBL, and plasma cell myeloma in real-time? Are there any overlapping features causing diagnostic challenges? How are you addressing these?
- Are you considering the role of specific markers and genetic abnormalities in diagnosis and prognosis as you interpret the results?
- Are you thinking about the next steps in management and the need for correlation with clinical findings?
On action
- What were the key clinical and laboratory findings that raised suspicion for chronic lymphocytic leukaemia (CLL), monoclonal B lymphocytosis (MBL), or plasma cell myeloma in the case(s) you investigated?
- What specific diagnostic techniques (morphology, immunophenotyping, cytogenetics, molecular, serum/urine electrophoresis, bone marrow biopsy with plasma cell quantification) were selected and (where applicable) performed?
- What were the key morphological features observed in the peripheral blood and bone marrow?
- What were the significant findings from immunophenotyping, cytogenetic, and molecular studies, as well as serum/urine electrophoresis results?
- How did these help differentiate between CLL, MBL, and myeloma?
- What are the diagnostic criteria for CLL, MBL, and plasma cell myeloma according to current guidelines (e.g., WHO classification, IMWG criteria for myeloma)?
- What are the characteristic morphological, immunophenotypic, cytogenetic, and molecular features of these disorders?
- How are these findings used to differentiate between these entities and to inform prognosis and treatment strategies?
- What is the clinical significance of MBL and its relationship to CLL?
- How will this experience enhance your ability to investigate and interpret results for suspected mature lymphoid neoplasms?
- What are the key resources and guidelines you will refer to in future practice for the diagnosis and classification of these disorders?
- How will you contribute to the integrated interpretation of results from a range of laboratory techniques in the context of mature lymphoid neoplasms?
Beyond action
- Have you been involved in the investigation of other cases of CLL, MBL, or plasma cell myeloma since this training activity, potentially encountering different stages of disease or clinical presentations?
- How did the diagnostic approach differ? Have you reviewed your reflect-on-action notes from this training activity? Has your understanding of the diagnostic criteria and the role of specific laboratory findings (e.g., immunophenotype in CLL, paraprotein in myeloma) evolved?
- Can you recall MDT discussions where the diagnosis, staging, or monitoring of these mature lymphoid neoplasms was discussed?
- What were the key laboratory contributions to these discussions? Have you reviewed current guidelines (e.g., WHO classification, NICE guidelines) related to the diagnosis and management of CLL, MBL, and plasma cell myeloma since this training activity?
- Has this training activity enhanced your ability to select and interpret the relevant laboratory tests for diagnosing and differentiating between these mature lymphoid neoplasms? Do you now have a better understanding of the diagnostic criteria for each entity, including the integration of clinical, morphological, immunophenotypic, and molecular findings?
- Has this experience influenced your understanding of the role of laboratory testing in monitoring disease progression and response to therapy in these conditions? Have the analytical and interpretative skills applied in this training activity been beneficial in other areas of haematological malignancy diagnostics?
- How will your experience in diagnosing and monitoring CLL, MBL, and plasma cell myeloma prepare you for managing these often indolent but sometimes progressive lymphoid disorders?
- Will your ability to accurately interpret diagnostic and monitoring data contribute to effective patient management and risk stratification? How might this experience support your potential involvement in research or the implementation of new diagnostic or prognostic markers in mature lymphoid neoplasms?
Relevant learning outcomes
| # | Outcome |
|---|---|
| # 3 |
Outcome
Perform a range of laboratory and molecular testing techniques to diagnose and monitor treatment of haematological malignancy in the correct clinical context, including the interpretation and reporting of results. |
| # 4 |
Outcome
Interpret and comply with national and international guidelines on the diagnosis and management of haematological cancer. |
| # 7 |
Outcome
Perform quality assurance and control tasks across the range of investigations. |